SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 4, 2021
Silverback Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction
500 Fairview Ave N, Suite 600
|(Address of principal executive offices)||(Zip Code)|
Registrants telephone number, including area code: (206) 456-2900
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|Common Stock, $0.0001 par value per share||SBTX||The Nasdaq Stock Market LLC|
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 4, 2021, Silverback Therapeutics, Inc. (the Company) held its 2021 Annual Meeting of Stockholders (the Annual Meeting). As of April 6, 2021, the record date for the Annual Meeting, 34,903,497 shares of common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below. Voting results are, when applicable, reported by rounding fractional share voting down to the nearest round number.
Proposal 1: Election of Directors
The Companys stockholders elected the three persons listed below as Class I directors, each to serve until the Companys 2024 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows:
|Votes For||Votes Withheld||Broker Non-Votes|
Vickie L. Capps
Robert Hershberg, M.D., Ph.D.
Maria Koehler, M.D., Ph.D.
Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm
The Companys stockholders ratified the selection by the Audit Committee of the Companys Board of Directors of Ernst & Young LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2021. The final voting results are as follows:
|Votes For||Votes Against||Abstentions||Broker Non-Votes|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|SILVERBACK THERAPEUTICS, INC.|
Laura Shawver, Ph.D.
Chief Executive Officer
Dated: June 9, 2021